Publications by authors named "M Gilestro"
The diagnosis of Waldenström's macroglobulinemia (WM), an IgM-associated lymphoplasmacytic lymphoma, can be challenging due to the different forms of disease presentation. Furthermore, in recent years, WM has witnessed remarkable progress on the diagnostic front, as well as a deeper understanding of the disease biology, which has affected clinical practice. This, together with the increasing variety of tools and techniques available, makes it necessary to have a practical guidance for clinicians to perform the initial evaluation of patients with WM.
View Article and Find Full Text PDFPurpose: High levels of circulating tumor plasma cells (CTC-high) in patients with multiple myeloma are a marker of aggressive disease. We aimed to confirm the prognostic impact and identify a possible cutoff value of CTC-high for the prediction of progression-free survival (PFS) and overall survival (OS), in the context of concomitant risk features and minimal residual disease (MRD) achievement.
Methods: CTC were analyzed at diagnosis with two-tube single-platform flow cytometry (sensitivity 4 × 10) in patients enrolled in the multicenter randomized FORTE clinical trial (ClinicalTrials.
Article Synopsis
- Minimal residual disease (MRD) assessment using multiparameter flow cytometry (MFC) is a key method for determining treatment effectiveness in newly diagnosed multiple myeloma (MM) patients.
- In a study of 321 patients, 76% were found to be MRD-negative at enrollment, with MRD-negative patients showing significantly better 5-year progression-free survival (66% vs. 31%) and overall survival (86% vs. 69%) compared to MRD-positive patients.
- The study also found that lenalidomide maintenance treatment increased the rate of patients transitioning from MRD-positive to MRD-negative after one year.
We analyzed variations in terms of chromosomal abnormalities (CA) by fluorescence in situ hybridization (FISH) analysis on purified bone marrow plasma cells throughout the progression from monoclonal gammopathy of undetermined significance/smoldering multiple myeloma (MGUS/SMM) to newly diagnosed MM/plasma cell leukemia (NDMM/PCL) at diagnosis and from diagnostic samples to progressive disease. High risk was defined by the presence of at least del(17p), t(4;14), and/or t(14;16). 1p/1q detection (in the standard FISH panel from 2012 onward) was not available for all patients.
View Article and Find Full Text PDF